[{"orgOrder":0,"company":"Boston Scientific","sponsor":"National PERT Consortium, Inc. | University Medical Center Mainz","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ National PERT Consortium, Inc. | University Medical Center Mainz","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ National PERT Consortium, Inc. | University Medical Center Mainz"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boston Scientific \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tremelimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ Boston Scientific","highestDevelopmentStatusID":"8","companyTruncated":"Boston Scientific \/ Boston Scientific"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TheraSphere (Yttrium-90 Glass Microspheres)","moa":"Emitter (radioisotope therapy)","graph1":"Oncology","graph2":"Phase III","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boston Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Polidocanol","moa":"Endothelium of blood vessels (Endothelium)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Foam","sponsorNew":"Boston Scientific \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ Boston Scientific","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ Boston Scientific"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ Boston Scientific","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ Boston Scientific"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ Boston Scientific","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ Boston Scientific"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boston Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Biocompatibles UK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"Yttrium Radioisotopes","moa":"Beta-radiation||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boston Scientific \/ Biocompatibles UK","highestDevelopmentStatusID":"8","companyTruncated":"Boston Scientific \/ Biocompatibles UK"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Urology","graph2":"Undisclosed","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Boston Scientific \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Boston Scientific

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Tremelimumab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          August 14, 2025

                          Lead Product(s) : Tremelimumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Center Eugene Marquis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Colchicine is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Atrial Fibrillation.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          January 09, 2025

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Recipient : Vivek Reddy

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : AGENT Drug-Coated Balloon is a paclitaxel-coated catheter delivering a therapeutic dose to treat coronary in-stent restenosis in patients with coronary artery disease.

                          Product Name : AGENT™ Drug-Coated Balloon

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          March 01, 2024

                          Lead Product(s) : Paclitaxel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Furosemide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 23, 2024

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Recipient : Heart Center Research, LLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Prasugrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of ST Elevation Myocardial Infarction.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 02, 2023

                          Lead Product(s) : Prasugrel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Recipient : Kindai University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Polidocanol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Varicose Veins.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 06, 2022

                          Lead Product(s) : Polidocanol

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Yttrium-90 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          October 01, 2021

                          Lead Product(s) : Yttrium Radioisotopes

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Biocompatibles UK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : TheraSphere (Yttrium-90 Glass Microspheres) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Hepatocellular.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 23, 2021

                          Lead Product(s) : TheraSphere (Yttrium-90 Glass Microspheres)

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : The trial, which will follow patients for one year, will assess whether treatment with the EKOS system in combination with anticoagulation is associated with a significant reduction in adverse events compared to anticoagulation alone, within seven days o...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 04, 2021

                          Lead Product(s) : Heparin Sodium

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Prostatic Hyperplasia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 09, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Urology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank